GET DAILY SIGNALSTreace Medical Concepts (TMCI) Narrows Losses in Q3 2026 With First Positive Adjusted EBITDA
Key Takeaways
- Treace Medical Concepts reported third quarter 2026 revenue of $48.3 million, down 4% from $50.2 million a year earlier.
- Net loss narrowed to $12.6 million, or $0.19 per share, from a loss of $16.3 million, or $0.26 per share, in the prior-year quarter.
- The company delivered its first positive adjusted EBITDA (adjusted earnings before interest, taxes, depreciation, and amortization) of $0.3 million, versus a $2.6 million loss a year ago.
- Results beat consensus on both lines, with EPS topping the -$0.25 estimate and revenue exceeding the roughly $47.7 million expectation.
- Full-year 2026 revenue guidance was narrowed to $206–$210 million, while the adjusted EBITDA loss outlook improved to $1–$2 million.
- Double-digit case-volume growth was offset by a mix shift toward lower-priced, minimally invasive products.
Why This Quarter Matters for Treace Medical Concepts
Treace Medical Concepts focuses on surgical solutions for bunions and midfoot deformities, with its Lapiplasty 3D Bunion Correction system at the core. This report stands out because the company is shifting from a single-product focus to a broader platform of bunion systems. I’m watching closely to see if rising procedure volumes can overcome the drag from lower-priced minimally invasive options and finally support revenue growth. After multiple quarters of sales pressure and widening losses, the results also highlight progress on cost control ahead of a typically stronger fourth quarter.
Breaking Down the Reported Figures
Revenue came in at $48.3 million for the third quarter of 2026, down 4% from $50.2 million in the same period last year. The decline stemmed from a greater share of lower-priced minimally invasive products and fewer bunion procedure kits sold, even as overall case volumes rose in double digits. The net loss improved 23% to $12.6 million, or $0.19 per share, compared with $16.3 million, or $0.26 per share, a year earlier.
Gross margin edged higher to 79.5% from 79.1%, and operating expenses dropped 10% to $49.9 million, driven mainly by lower sales and marketing costs. Adjusted EBITDA turned positive at $0.3 million, marking the first such result after a $2.6 million loss in the prior-year quarter. On a GAAP basis the company still posted a net loss. Cash, cash equivalents, and marketable securities stood at $39.8 million as of September 30, 2026.
Management tightened full-year 2026 revenue guidance to $206–$210 million, implying a 1% to 3% decline from 2025, and improved the adjusted EBITDA loss target to $1–$2 million from the previous $3–$5 million range. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Investor Reaction and What the Market Is Pricing In
Expectations ahead of the release were tempered, with the stock already trading well below year-ago levels and analysts anticipating continued revenue softness. The beats on both revenue and EPS, together with the positive adjusted EBITDA milestone, provided some reassurance around the path to profitability. Still, the tightened revenue outlook and persistent top-line decline highlight the core challenge: volumes are expanding, yet pricing pressure from newer systems is limiting the translation to revenue. Much will depend on whether the fourth quarter delivers the usual seasonal lift and shows a return to growth.
Looking Ahead: Factors Worth Monitoring
Guidance points to fourth-quarter revenue of roughly $65–$69 million, which would mark a return to year-over-year growth after the third-quarter dip. Management expects this to come from sustained volume gains, a reduced impact from the 2025 product-mix shift, and contributions from 2026 launches. Key items to track include whether stocking orders from distributors fade as anticipated and whether underlying revenue trends remain positive on an adjusted basis. Adoption of newer systems by existing Lapiplasty users will also be telling, as will the timing of the Lapiplasty Lightning launch, now slated for a full rollout in the first quarter of 2027 rather than a limited fourth-quarter introduction. Broader elective-procedure trends across the industry remain relevant as well. From what I see, the ability to convert case growth into revenue while maintaining the improved margin and cash trajectory will be the clearest signal when fourth-quarter results arrive.
Using AI Tools in My Research Process
When reviewing healthcare names like this one, I occasionally turn to data-driven platforms to cross-check fundamentals and spot comparable opportunities. One tool that has proven useful is Tickeron’s AI Screener, which lets me filter by technical patterns, valuation metrics, and industry trends in a structured way. It helps surface ideas efficiently without replacing my own fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TMCI in upward trend: 10-day moving average broke above 50-day moving average on November 02, 2026
The 10-day moving average for TMCI crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +5.39% 3-day Advance, the price is estimated to grow further. Considering data from situations where TMCI advanced for three days, in 203 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 129 of 162 cases where TMCI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Bearish Trend Analysis
The 10-day RSI Indicator for TMCI moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 24 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TMCI as a result. In 78 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for TMCI turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 39 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
TMCI moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TMCI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
TMCI broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.869) is normal, around the industry mean (4.137). P/E Ratio (-4.380) is within average values for comparable stocks, (2.620). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.430) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 40 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. TMCI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TMCI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What is a Consolidated Tax Return?
Can I Hold Bitcoins and other Cryptocurrencies in an IRA?
How Do Reverse Mergers Offer a Shortcut to Going Public?
[Test] Automate Your Success: Explore Tickeron's Top 10 Stock Trading Robots Now!
The Apple Empire Forecast 2030: Why the Market May Still Be Underpricing a +$5 Trillion Ecosystem
General Information
Industry MedicalNursingServices
Advertisement